Repros Therapeutics Inc. on Wednesday reported a net loss for the fourth quarter, ended Dec. 31, of $5.4 million, or 54 cents loss per diluted share, on revenue of $110,000, compared with net loss of $2.3 million, or 22 cents loss per share, on revenue of $174,000 for the same period in 2005.
The Woodlands-based pharmaceutical company said the loss was due to increased spending in its clinical development programs and an increase in non-cash, stock option compensation expenses.
Analysts polled by Thomson Financial expected Repros (NASDAQ: RPRX) to post a net loss of 41 cents per share.
For the full year, the net loss was $14.2 million, or $1.40 loss per diluted share, on revenue of $596,000, compared with a net loss of $7.4 million, or 77 cents loss per share, on revenue of $634,000, in 2005.
In December, the company revealed that its endometriosis drug, Proellex, helped significantly reduce pain in female patients compared to current available treatment in a European Phase 2 clinical trial.